For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins.

TitleBiochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins.
Publication TypeJournal Article
Year of Publication2009
AuthorsDey AK, David KB, Lu M, Moore JP
JournalVirology
Volume385
Issue1
Pagination275-81
Date Published2009 Mar 1
ISSN1096-0341
KeywordsCell Line, env Gene Products, Human Immunodeficiency Virus, Glycoproteins, HIV-1, Humans, Protein Multimerization, Protein Stability, Ultracentrifugation
Abstract

Human immunodeficiency virus type 1 (HIV-1) entry into host cells is mediated by the trimeric envelope glycoprotein complex (Env). Accordingly, the Env proteins are the targets for neutralizing antibodies (NAbs) and are the focus of vaccines intended to induce NAbs. Because the Env complex is labile, soluble recombinant Env (gp140) trimers require engineering to stabilize them sufficiently for use as immunogens. Trimeric forms of gp140 trimers can be created that are either cleavage-competent or cleavage-defective at the junction between the gp120 and gp41 subunits. As functional trimers are cleaved at this site, the question arises as to whether cleavage affects the antigenic structure of the Env complex in a way that is relevant to vaccine design. Here, we present a comparative analysis of the antigenicity profiles of cleaved and uncleaved gp140 trimers derived from the KNH1144 (subtype A) virus that are otherwise closely sequence-matched. While cleavage did not affect the exposure of NAb epitopes on the gp140 trimers, non-neutralizing antibodies to gp41 epitopes bound much more strongly to uncleaved trimers. Hence cleavage does alter the structure of the HIV-1 Env complex.

DOI10.1016/j.virol.2008.12.009
Alternate JournalVirology
PubMed ID19135223
PubMed Central IDPMC3795524
Grant ListAI 30030 / AI / NIAID NIH HHS / United States
AI 45463 / AI / NIAID NIH HHS / United States
R01 AI045463 / AI / NIAID NIH HHS / United States

Weill Cornell Medicine Microbiology and Immunology 1300 York Avenue, Box 62 New York, NY 10065 Phone: (212) 746-6505 Fax: (212) 746-8587